ArticleTherapeutic advances in medical oncology2025
A retrospective study of clinical characteristics and steroid therapy in immune checkpoint inhibitor-mediated hepatitis.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prediction of Immune Checkpoint Inhibitor-Induced Liver Injury in Patients with Gastrointestinal Cancer: Machine Learning Modeling for Time-Stratified Risk Assessment.Current oncology (Toronto, Ont.) · 2026Article
- Risk Factors and Biomarkers for Immune Checkpoint Inhibitor-mediated Hepatotoxicity: Emerging Insights and Future Perspectives.Journal of clinical and translational hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the widespread clinical application of immune checkpoint inhibitors (ICIs), immune-mediated hepatitis (IMH) has become increasingly prevalent. Objectives: This study aims to analyze the clinical characteristics, steroid treatment, and prognosis of IMH patients, providing further evidence to enhance the safety of ICIs in clinical practice. Design: A retrospective cohort study included tumor patients who received ICI therapy. Comprehensive analyses were conducted to explore the factors influencing the occurrence, clinical characteristics, and prognosis of IMH. Methods: Tumor patients treated with PD-1/PD-L1 inhibitors were enrolled in our study. Patients were stratified based on the occurrence and severity of IMH, as well as the administration of glucocorticoid therapy, to investigate the risk factors for IMH development, critical factors influencing IMH progression, and treatment-specific outcomes. Results: Of 744 patients, 341 (45.8%) developed IMH. IMH was significantly more frequent in females ( Conclusion: Female gender, younger age (<45 years), HCC, and gastric cancer are independent risk factors for IMH. Younger patients are more likely to develop severe IMH. Glucocorticoid therapy is beneficial, particularly in grade 3-4 IMH. Early detection, prompt intervention, and tailored management strategies may help mitigate progression and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.